Graft Versus Host Disease (GVHD) Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Biocon, Xenikos, MaaT Pharma, Syndax Pharmaceuticals, Chia Tai

Posted on
by

Graft Versus Host Disease (GVHD) Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Biocon, Xenikos, MaaT Pharma, Syndax Pharmaceuticals, Chia Tai
DelveInsight’s “Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Graft Versus Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graft Versus Host Disease Market Forecast

 

Some of the key facts of the Graft Versus Host Disease Market Report: 

  • The Graft Versus Host Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to HRSA (2022), there were more than 8,000 allogeneic transplant patients in the US in 2013, and 9,498 transplants are anticipated in 2019, up from 9,509 in 2018
  • According to Passweg et al. (2021), more transplants are being performed in European nations. Around 41% of all HSCT in 2018 were allogeneic, whereas 59% were autologous
  • In 2022, there were 51,540 GvHD cases in the 7MM as a whole. With about 23,150 cases in 2022, the United States had the most GvHD cases overall. During the study period (2019–2032), it is anticipated that these numbers will rise
  • Acute GvHD incident cases were 10,340 in the 7MM, while chronic GvHD five-year prevalence was 23,080 in 2022, with an expected rise to 2032
  • The total number of hematopoietic stem-cell and allogenic transplant cases in the United States were 24,510 and 10,260, respectively, in 2022, and are projected to rise by 2032
  • About 4,780 and 17,210 cases of aGvHD and cGvHD, respectively, received first-line care in the US in 2022. By 2032, more of these cases are anticipated, according to the report
  • In October 2022, For the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD), Mesoblast Limited announced that it had submitted to the U.S. Food and Drug Administration (FDA) significant new information on clinical and potency assay items identified in the Complete Response Letter (CRL) it had received from FDA in September 2020.
  • In August 2022, Imbruvica from Johnson & Johnson and AbbVie was given FDA approval to treat chronic graft-versus-host disease in children aged 1 to 11. For this age group, it is the first available therapeutic choice. Imbruvica’s use for people with cGVHD aged 12 and older received FDA approval for the first time in 2017.
  • In June 2022, A global pivotal Phase III clinical study comparing T-Guard and ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) after allogeneic hematopoietic stem cell transplant (allo-HSCT) has enrolled its first patient, according to Xenikos B.V
  • Key Graft Versus Host Disease Companies: Biocon, Xenikos, MaaT Pharma, Syndax Pharmaceuticals,  Chia Tai Tianqing Pharmaceutical Group, CSL Behring, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Mallinckrodt, Mesoblast, Inc., Astellas Pharma, Syndax Pharmaceuticals, and others
  • Key Graft Versus Host Disease Therapies: Itolizumab, T-Guard, MaaT013, Axatilimab, TQ 05105, CSL 964 AAT (zemaira), RGI-2001, Defibrotide, Ibrutinib, Imatinib Mesylate and Nilotinib, Panobinostat (LBH589), Methylprednisolone, Prochymal®, Methotrexate, Uvadex, Axatilimab, and others
  • The Graft Versus Host Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graft Versus Host Disease pipeline products will significantly revolutionize the Graft Versus Host Disease market dynamics.

 

Graft Versus Host Disease Overview

Graft-versus-host disease (GvHD) is an immune disorder that develops after an allogeneic bone marrow transplant (stem cell transplant) when immune cells (T cells) from the donor (also referred to as the graft or graft cells) attack the recipient patient host’s tissues (healthy cells).

 

Get a Free sample for the Graft Versus Host Disease Market Report 

https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market

 

Graft Versus Host Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Graft Versus Host Disease Epidemiology Segmentation:

The Graft Versus Host Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Graft Versus Host Disease
  • Prevalent Cases of Graft Versus Host Disease by severity
  • Gender-specific Prevalence of Graft Versus Host Disease
  • Diagnosed Cases of Episodic and Chronic Graft Versus Host Disease

 

Download the report to understand which factors are driving Graft Versus Host Disease epidemiology trends @ Graft Versus Host Disease Epidemiology Forecast

 

Graft Versus Host Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graft Versus Host Disease market or expected to get launched during the study period. The analysis covers Graft Versus Host Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graft Versus Host Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Graft Versus Host Disease Therapies and Key Companies

  • Itolizumab: Biocon
  • T-Guard: Xenikos
  • MaaT013: MaaT Pharma
  • Axatilimab: Syndax Pharmaceuticals
  • TQ 05105: Chia Tai Tianqing Pharmaceutical Group
  • CSL 964 AAT (zemaira): CSL Behring
  • MaaT013: MaaT Pharma
  • RGI-2001: Regimmune
  • Defibrotide: Jazz Pharmaceuticals
  • Ibrutinib: Pharmacyclics LLC.
  • Imatinib Mesylate and Nilotinib: Novartis
  • Panobinostat (LBH589): Novartis
  • Methylprednisolone: Mallinckrodt
  • Prochymal®: Mesoblast, Inc.
  • Methotrexate: Astellas Pharma
  • Uvadex: Mallinckrodt
  • Axatilimab: Syndax Pharmaceuticals

 

Discover more about therapies set to grab major Graft Versus Host Disease market share @ Graft Versus Host Disease Treatment Market

 

Graft Versus Host Disease Market Strengths

  • Pipeline of GvHD is very robust and several late stage assets are expected to enter in to the market very soon. GvHD pipeline consists of small molecules, monoclonal and Bi-specific antibody, stem cell therapy, recombinant fusion protein etc. which will provide the patients and physicians more options in future.

 

Graft Versus Host Disease Market Opportunities

  • Several upcoming therapies have received Orphan designations, therapies can get accelerated approval time, 7 years of market exclusivity in the US, clinical trials subsidies and reduced regulatory fees and others. Companies can also go for premium pricing as well.

 

Scope of the Graft Versus Host Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Graft Versus Host Disease Companies: Biocon, Xenikos, MaaT Pharma, Syndax Pharmaceuticals,  Chia Tai Tianqing Pharmaceutical Group, CSL Behring, MaaT Pharma, Regimmune, Jazz Pharmaceuticals, Pharmacyclics LLC., Novartis, Mallinckrodt, Mesoblast, Inc., Astellas Pharma, Syndax Pharmaceuticals, and others
  • Key Graft Versus Host Disease Therapies: Itolizumab, T-Guard, MaaT013, Axatilimab, TQ 05105, CSL 964 AAT (zemaira), RGI-2001, Defibrotide, Ibrutinib, Imatinib Mesylate and Nilotinib, Panobinostat (LBH589), Methylprednisolone, Prochymal®, Methotrexate, Uvadex, Axatilimab, and others
  • Graft Versus Host Disease Therapeutic Assessment: Graft Versus Host Disease current marketed and Graft Versus Host Disease emerging therapies
  • Graft Versus Host Disease Market Dynamics: Graft Versus Host Disease market drivers and Graft Versus Host Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Graft Versus Host Disease Unmet Needs, KOL’s views, Analyst’s views, Graft Versus Host Disease Market Access and Reimbursement 

 

To know more about Graft Versus Host Disease companies working in the treatment market, visit @ Graft Versus Host Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Graft Versus Host Disease Market Report Introduction

2. Executive Summary for Graft Versus Host Disease

3. SWOT analysis of Graft Versus Host Disease

4. Graft Versus Host Disease Patient Share (%) Overview at a Glance

5. Graft Versus Host Disease Market Overview at a Glance

6. Graft Versus Host Disease Disease Background and Overview

7. Graft Versus Host Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graft Versus Host Disease 

9. Graft Versus Host Disease Current Treatment and Medical Practices

10. Graft Versus Host Disease Unmet Needs

11. Graft Versus Host Disease Emerging Therapies

12. Graft Versus Host Disease Market Outlook

13. Country-Wise Graft Versus Host Disease Market Analysis (2019–2032)

14. Graft Versus Host Disease Market Access and Reimbursement of Therapies

15. Graft Versus Host Disease Market Drivers

16. Graft Versus Host Disease Market Barriers

17.  Graft Versus Host Disease Appendix

18. Graft Versus Host Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services